← All trials
NCT03465111
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2018
- Primary completion
- Sep 30, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Metropolitan Eye Research and Surgery InstituteLead sponsor
- Cornell UniversityCollaborator
- Stanford UniversityOverall official - principal investigator
- Stanford UniversityCollaborator
- University of LouisvilleOverall official - principal investigator
- University of LouisvilleCollaborator
- MallinckrodtCollaborator
- Colorado Retina AssociatesCollaborator
- Colorado Retina InstituteOverall official - principal investigator
- Metropolitan Eye Research and Surgery InstituteOverall official - principal investigator
- Ocular Imaging Research and Reading CenterCollaborator
- Texas Retina AssociatesOverall official - principal investigator
- Texas Retina AssociatesCollaborator
- Cornell UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.